how long should you stay on retatrutide UK Research Library The biggest mistake isn't taking

In 2025, Ozempic was approved by the US Food and Drug Administration (FDA) to reduce the risk of worsening kidney disease and kidney failure in people with type 2 diabetes

We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery

With the increasing popularity of GLP-1 medications for weight loss, many women have questions about interactions between GLP-1 medications and birth control

The median follow-up duration was 1 year (IQR: 0.52 years), with key findings including a median weight loss of 11.7 kg and a median BMI at the most recent follow-up of 31.2 kg/m 2 , reflecting a median reduction of 3.7 kg/m 2

Two commonly used GLP-1 agonists are Semaglutide and Tirzepatide

Chen, Bulent Tolga Delibasi, James Wang, Thomas Tran, Connie Hu, Charles W